Regen BioPharma, Inc.
RGBP
$0.055
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -174.99% | -166.08% | -101.31% | -157.80% | -52.67% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 3,122.22% | 215.91% | -63.91% | -89.09% | -98.73% |
| Total Other Non-Cash Items | -39.85% | 15.87% | 95.36% | 90.13% | 3,655.97% |
| Change in Net Operating Assets | 88.90% | 94.54% | 99.93% | 102.09% | 38.53% |
| Cash from Operations | -298.56% | -140.71% | -76.88% | 3.72% | 71.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -92.17% | 43.08% | 43.08% | 48,660.00% | 48,660.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 134.95% | 525.67% | 370.15% | 81,820.00% | 359.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -272.35% | 155.39% | 93.47% | 126.79% | 110.33% |